The Food and Drug Administration (FDA) has given final approval for cetirizine hydrochloride syrup (Zyrtec), according to Taro Pharmaceutical Industries.
The Food and Drug Administration (FDA) has given final approval for the generic version of cetirizine hydrochloride syrup (Zyrtec), according to Taro Pharmaceutical Industries.
Taro's cetirizine hydrochloride syrup is a bioequivalent to McNeil Consumer Healthcare's Zyrtec Syrup 1 mg/mL, and is used for symptom relief associated with perennial allergic rhinitis in children 6 to 23 months old and for chronic urticaria in children 6 months to 5 years old. Taro had received tentative FDA approval for Zyrtec in October 2007.
Further details on the approval may be found on the FDA website.
